Skip to main content
S 1334 117th Congress Senate Environmental Protection Blood and blood diseases Civil actions and liability Environmental assessment, monitoring, research Environmental health Federal district courts Hazardous wastes and toxic substances Health care costs and insurance Health care coverage and access Health promotion and preventive care Manufacturing Medical research Medical tests and diagnostic methods Pollution liability

PFAS Accountability Act of 2021

Introduced: April 22, 2021 Introduced by: Gillibrand, Kirsten E. Democratic · New York See on congress.gov
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Apr 22, 2021
Read twice and referred to the Committee on Environment and Public Works.
Apr 22, 2021
Introduced in Senate
 Plain-English summary Congressional Research Service

PFAS Accountability Act of 2021

This bill provides a cause of action under the Toxic Substances Control Act for individuals or classes of individuals who were significantly exposed to perfluoroalkyl or polyfluoroalkyl substances, commonly referred to as PFAS. These substances are man-made and may have adverse human health effects. A variety of products contain the compounds, such as nonstick cookware or weatherproof clothing.

Specifically, the bill provides a cause of action those who were significantly exposed to PFAS (or have reasonable grounds to believe they were exposed) against persons who engaged in any portion of a manufacturing process that created the PFAS and foresaw (or reasonably should have foreseen) the creation or use of PFAS would result in human exposure.

The bill authorizes a court to award medical monitoring to claimants if (1) they have been significantly exposed to PFAS, (2) they have an increased risk of developing a disease associated with such exposure, (3) the increased risk provides a reasonable basis to conclude that periodic diagnostic medical examinations is necessary, and (4) the medical examinations are effective in detecting a disease associated with PFAS exposure.

The bill establishes a presumption of significant exposure to PFAS if the claimant (1) provides medical results proving the presence of PFAS in the body, or (2) demonstrates the defendant's manufacturing process created the PFAS to which the claimant was exposed and the PFAS were released into one or more areas where the claimant would have been exposed for at least one year.

What's happening now April 22, 2021

Read twice and referred to the Committee on Environment and Public Works.

 Committees of jurisdiction 1